Oral GLP-1 Pills for Weight Loss (2026): Foundayo, Oral Semaglutide (Wegovy) & All Options
As of 2026, two FDA-approved oral GLP-1 pills exist for weight loss: Foundayo (orforglipron, 12.4% weight loss, $149/mo self-pay via LillyDirect, no fasting needed, approved April 1) and the Wegovy pill (semaglutide 25mg, 16.6% weight loss, $1,349/mo list price, requires 30-min fast before dosing, approved December 2025). Rybelsus is oral semaglutide but approved for type 2 diabetes only, not weight loss.
Summarize this article with
As of 2026, two FDA-approved oral GLP-1 pills exist for weight loss: Foundayo (orforglipron) and the Wegovy pill. Foundayo (Eli Lilly) was approved April 1, 2026, the first non-peptide small-molecule GLP-1 agonist, achieving 12.4% mean body weight loss at 72 weeks in the ATTAIN-1 Phase 3 trial published in the New England Journal of Medicine. Oral Wegovy (Novo Nordisk's semaglutide 25mg tablet) was approved December 2025, achieving 16.6% mean body weight loss at 68 weeks in the OASIS Phase 3 trial. Both require a prescription. The core difference: Foundayo has no fasting requirement and costs from $149/month self-pay; the Wegovy pill requires a 30-minute pre-dose fast and costs $1,349/month at list price.
Quick answer, which oral GLP-1 pill is right for you:
- •No fasting, simplest routine: Foundayo from $149/mo via LillyDirect, take any time, any meal. Full Foundayo guide.
- •Highest weight loss from a pill: Wegovy pill, 16.6% vs Foundayo's 12.4%; $25/mo with commercial insurance + savings card. Wegovy pill vs injection guide.
- •Head-to-head clinical comparison: Foundayo vs Wegovy pill, trial data, efficacy, side effects, and cost side by side.
- •Want an injectable instead: Cheapest tirzepatide from $149/mo (20.9% weight loss) or see all cheapest GLP-1 medication options ranked by price.
This guide covers every FDA-approved oral GLP-1 option for weight loss, how they compare on efficacy, cost, and convenience, and who each pill is best suited for. For personalized help choosing, take the 60-second match quiz.
Comparing your options?
See every verified GLP-1 program ranked side by side on cost, safety, and care quality.
Compare all 52GLP-1 providers →The 2 FDA-Approved Oral GLP-1 Pills for Weight Loss
Rybelsus is often confused with oral weight-loss GLP-1 pills, it is oral semaglutide, but at 3–14mg daily doses approved only for type 2 diabetes management. It's not FDA-approved for obesity and is not covered under weight-loss benefit pathways. The two FDA-approved oral GLP-1 options for weight loss in 2026 are Foundayo and the Wegovy pill:
| Foundayo (Orforglipron) | Wegovy Pill (Semaglutide 25mg) | Rybelsus (Semaglutide 7–14mg) | |
|---|---|---|---|
| FDA weight-loss approval | April 1, 2026 | December 2025 | Not approved for weight loss |
| Active ingredient | Orforglipron (small molecule, non-peptide) | Semaglutide (peptide) | Semaglutide (peptide) |
| Mechanism | GLP-1 receptor agonist | GLP-1 receptor agonist | GLP-1 receptor agonist (diabetes use) |
| Dosing frequency | Once daily | Once daily | Once daily |
| Fasting required | No, take any time | Yes, 30 min before food/drinks | Yes, 30 min before food/drinks |
| Phase 3 weight loss | 12.4% at 72 weeks (ATTAIN-1, NEJM) | 16.6% at 68 weeks (OASIS, NEJM) | N/A (diabetes primary endpoint) |
| List price | $649/mo (WAC) | $1,349/mo (WAC) | ~$1,028/mo (diabetes coverage) |
| Lowest self-pay cost | $149/mo via LillyDirect (starter dose) | $25/mo with commercial ins + savings card | Via insurance with T2D diagnosis only |
| Cardiovascular label | Pending | Yes, SELECT trial (20% MACE reduction) | Yes |
Every Tuesday. One email. The cheapest verified GLP-1 programs of the week.
Price drops, FDA alerts, new programs ranked, and compounded shortages, delivered Tuesday morning. No filler. Unsubscribe anytime.
No affiliate spam. No retargeting pixels. Unsubscribe in one click.
Foundayo (Orforglipron): The No-Fasting Oral GLP-1
Foundayo is the first non-peptide GLP-1 pill, a small-molecule oral drug, not a biological peptide. This structural difference is why it doesn't degrade in stomach acid and requires no fasting before dosing. You can take it any time of day, with or without food or water. Foundayo was FDA-approved on April 1, 2026 for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).
Cost: Foundayo's WAC (list price) is $649/month. Self-pay via LillyDirect: $149/month at the starter dose (12mg), rising to $299/month at full maintenance dosing (36–45mg). With commercial insurance + Eli Lilly's savings card: $25/month (same copay as Zepbound). Foundayo is now dispensed through Amazon Pharmacy, GoodRx, LillyDirect, and select telehealth platforms including Found and Ro. Coverage is expanding, CVS Caremark added Foundayo to its standard commercial formulary effective June 1, 2026, covering ~25–30 million Americans. CVS also announced Zepbound formulary restoration effective October 1. Express Scripts and OptumRx decisions pending as of June 2026.
Side effects: Foundayo's most common side effects are gastrointestinal, nausea (32% vs 9% placebo), diarrhea (18%), constipation (13%), and vomiting (11%) in ATTAIN-1. Side effects were most frequent during dose escalation and decreased at steady state. No thyroid C-cell tumor warning (which appears on semaglutide and tirzepatide labeling) is present on Foundayo's label, given the different molecular mechanism.
Who is Foundayo best for? Patients who want to avoid injections, dislike strict meal-timing requirements, or are switching off compounded semaglutide injectable (the ATTAIN-MAINTAIN trial showed patients maintained nearly all their injectable GLP-1 weight loss after switching to Foundayo). The $149/month LillyDirect self-pay price makes it competitively priced against compounded injectables, with the advantage of FDA-approved status.
Not sure which GLP-1 program is right for you?
Take the 60-second quiz, we'll match you against 52 verified providers on your goals, budget, and medication preference, then surface your top 3.
Take the 60-sec QuizOral Wegovy (Semaglutide 25mg): Higher Efficacy, Higher Price
Oral Wegovy is semaglutide, the same active ingredient as injectable Wegovy (2.4mg/week) and Ozempic, but formulated as a 25mg daily tablet using absorption technology that achieves adequate bioavailability in pill form. It was FDA-approved in December 2025, a few months before Foundayo's April 2026 approval.
Real-world launch data (ADA 2026): In data presented at the ADA 86th Scientific Sessions (June 7, 2026), Novo Nordisk reported that oral Wegovy has surpassed 3 million prescriptions in just over five months since becoming available in January 2026, roughly one prescription filled every five seconds, making it one of the fastest US pharmaceutical launches by prescription volume on record. The first million prescriptions came in 12 weeks; the next two million followed in 10 weeks. Crucially, more than 80% of oral Wegovy prescriptions are for people who had never previously taken a GLP-1 medication, confirming the pill format is expanding obesity treatment access rather than simply converting existing injectable users.
The fasting requirement is the main practical challenge. Oral Wegovy must be taken with ≤4oz of plain water, on an empty stomach, at least 30 minutes before eating, drinking anything caloric, or taking other oral medications. This is because semaglutide is a peptide that degrades rapidly when food is present. Patients who forget to take it before breakfast cannot take it with food, they must wait for the next day's dose. For patients with consistent early-morning routines, this is manageable; for shift workers or those with irregular schedules, it adds friction.
Cost: $1,349/month at list price. With commercial insurance + Novo Nordisk's savings card: $25/month. Without insurance, oral Wegovy is significantly more expensive than Foundayo's $149/month LillyDirect self-pay option. One coverage advantage oral Wegovy holds: it carries an FDA cardiovascular risk reduction label, extended from the landmark SELECT trial (20% reduction in MACE in adults with obesity and established cardiovascular disease). This can unlock coverage through cardiovascular benefit pathways when standard weight-loss coverage is denied.
Side effects: Similar GI profile to Foundayo, nausea, diarrhea, constipation, vomiting, most common during dose escalation. Oral Wegovy carries the standard semaglutide boxed warning about thyroid C-cell tumors (rodent data, unknown human relevance) and contraindication in patients with personal/family history of medullary thyroid carcinoma or MEN2.
Which Oral GLP-1 Pill Should You Take?
The choice between Foundayo and the Wegovy pill comes down to three factors: fasting tolerance, insurance coverage, and weight-loss priority. Neither pill requires a history of prior GLP-1 use, both are first-line options for eligible patients.
| Your situation | Recommended pill |
|---|---|
| Can't commit to a 30-min morning fast | Foundayo, no timing restrictions |
| Have commercial insurance with GLP-1 coverage | Compare both at $25/mo copay, pick Wegovy pill for higher efficacy |
| Paying fully out-of-pocket | Foundayo via LillyDirect ($149/mo) vs Wegovy pill ($1,349/mo list) |
| Have cardiovascular disease + obesity | Wegovy pill, FDA cardiovascular label; Foundayo CV data still pending |
| Switching from injectable GLP-1 to a pill | Foundayo, ATTAIN-MAINTAIN data shows weight maintained after switching from injectables |
| Highest possible weight loss from a pill is the priority | Wegovy pill, 16.6% vs Foundayo's 12.4% at comparable timepoints |
| Taking multiple morning medications | Foundayo, no drug-timing interaction with food or other pills |
| On Medicare Part D | Both pills qualify for $50/mo flat copay via Medicare GLP-1 Bridge starting July 1, 2026 |
Both pills are for the same FDA-approved indication: adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity. Neither is appropriate for patients under 18. For a full side-by-side breakdown including nausea rates, titration schedules, and head-to-head framing of the efficacy difference, see Foundayo vs Wegovy pill. To compare oral options against the full range of GLP-1 programs including injectables, see the GLP-1 provider rankings or take the match quiz for a personalized recommendation.
Sources
- Orforglipron (Foundayo), ATTAIN-1 Phase 3 Trial (NEJM, 2025)
- Oral Semaglutide for Obesity, OASIS Phase 3 Trial (NEJM)
- FDA Drug Approvals Database, Foundayo (Orforglipron), April 1, 2026
- FDA Approves Oral Wegovy, Novo Nordisk Press Release, December 2025
- SELECT Trial, Cardiovascular Outcomes with Semaglutide in Obesity (NEJM)
- ATTAIN-MAINTAIN, Maintaining Weight After Switching from Injectable to Oral GLP-1 (Lilly)
- ACHIEVE-3, Orforglipron vs Oral Semaglutide Head-to-Head in Type 2 Diabetes (The Lancet, 2026)00202-3/abstract)
- Wegovy Pill Surpasses 3 Million Prescriptions, Novo Nordisk Press Release, ADA 2026 (June 7, 2026)
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any medication. Information is current as of the publication date but may change.
Affiliate Disclosure: Some links in this article are affiliate links. We may earn a commission if you sign up through our links, at no extra cost to you.
Done comparing? Our Top Pick is Yucca Health
Our featured pick, scored 7.7/10 by our methodology, at $146/mo all-in. Not sure it's the one for you? The 60-second quiz matches you to your budget and medication.
Featured affiliate pick, we may earn a commission · scores set by our methodology, not payment
Compare every GLP-1 program in one place
See all 52 verified providers ranked side by side on price, medication, and our independent score, or jump straight to the cheapest verified prices.
Medicare & GLP-1
Medicare GLP-1 Coverage Guide
Saw Medicare mentioned in "Oral GLP-1 Pills for Weight Loss (2026): Foundayo, Oral Semaglutide (Wegovy) & All Options"? Here's exactly what's covered, who qualifies, and how the $50/mo Bridge copay works from July 1, 2026.
Read the Medicare Coverage Guide →Foundayo vs Wegovy Pill (2026): 16.6% vs 12.4% Weight Loss, $149 vs $1,349/mo Self-Pay
GuidesFoundayo (Orforglipron) Guide 2026: from $149/mo Self-Pay, 12.4% Weight Loss, No Fasting Required
News & PipelineFoundayo Ships Week 2: How to Order Eli Lilly's GLP-1 Pill Right Now (April 2026)
What the doctors say
Verbatim, independently sourced statements from named physicians and medical bodies, real clinicians quoted with their sources, not a single paid reviewer. General clinical context, not an endorsement of any provider.
“For more than a million people at high risk of heart attack and stroke, this treatment on the NHS could be life-changing – offering a powerful new way to protect their hearts and improve their health.”
“So-called 'weight loss drugs' like semaglutide have proven benefits beyond reducing the number on the scales – they are now considered important medicines for preventing deadly heart attacks and strokes. Today's guidance will no doubt help save lives as cardiovascular disease is still one of the country's biggest killers.”
“While compounding can play an appropriate role when used to meet the specific needs of an individual patient, the large-scale production and marketing of compounded versions of these medicines raises serious safety risks when products have not undergone the rigorous scientific and regulatory review required for FDA-approved therapies.”
Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.